Clinical trials: Retinal Dystrophies
Retinitis Pigmentosa
Phase 1 Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa
In this Phase 1 open-labeled prospective study, one eye of each participant with vision loss from retinitis pigmentosa will be administered intravitreal injection of autologous CD34+ stem cells harvested from bone marrow.
- Trial name
- BMSCRP1 (NCT04925687)
- Testing
- Intravitreal autologous CD34+ cells
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of California, Davis
Retinitis Pigmentosa (RP)
Prospective, Randomized, Sham-controlled, Dose-finding I/II Trial of Safety and Efficacy of Modified Optogenetic Gene Therapy (ZM-02 Injection)
This is a Phase 1/2, multi-center, randomized, sham-controlled, dose-escalation study evaluating ZM-02 in patients with advanced retinitis pigmentosa (RP).
- Trial name
- PRISM (NCT07282457)
- Testing
- ZM-02 (low dose), ZM-02 (high dose), ZM-02 (selected dose)
- Volunteers
- 21 people
- Sponsor
- Zhongmou Therapeutics
Retinitis Pigmentosa
Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
This study evaluates the safety of a single injection of jCell (famzeretcel) comprising 6.0 million (6.0M) retinal progenitor cells over a six-month study period in a cohort of adult subjects with RP.
- Trial name
- NCT06912633
- Testing
- human retinal progenitor cells, Mock injection
- Where
- 12 sites in United States
- Volunteers
- 31 people
- Sponsor
- jCyte, Inc
Retinitis Pigmentosa
The FIGHT-RP1 Study
Retinitis Pigmentosa (RP) is a devastating eye disease and at present there are no known treatment options that can alter the rate of vision loss.
- Trial name
- FIGHT-RP1 (NCT03063021)
- Testing
- N-Acetyl Cysteine (NAC)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Johns Hopkins University
Retinitis Pigmentosa, Eye Diseases
Rate of Progression in EYS Related Retinal Degeneration
The overall goal of this project funded by the Foundation Fighting Blindness is to characterize the natural history of disease progression in patients with EYS mutations in order to accelerate the development of outcome measures…
- Trial name
- Pro-EYS (NCT04127006)
- Where
- 19 sites in United States, Canada and 5 more
- Volunteers
- 103 people
- Sponsor
- Jaeb Center for Health Research
Pigmentary Retinopathy
Mobility Protocol Adapted for Advanced Visually Impaired Subjects
Retinitis Pigmentosa is characterized by a progressive disappearance of photoreceptors, responsible for a progressive and severe loss of vision.
- Trial name
- PROMA (NCT04419285)
- Testing
- Locomotion task, Posturology task SOT (Sensory Organization Test), The quality of life questionnaire
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Retinitis Pigmentosa
Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors
The outcome of this trial will reveal the possibilities of the retinal implant to improve the situation of patients with hereditary retinal blindness caused by degenerations of the outer retina.
- Trial name
- NCT00515814
- Testing
- Retina implant is surgically placed into subretinal position
- Where
- 2 sites in Germany
- Volunteers
- 15 people
- Sponsor
- Retina Implant AG
Retinitis Pigmentosa, Maculopathy, Age Related
Bimodal and Coaxial High Resolution Ophtalmic Imaging
The knowledge of the pathogenesis of retinal affections, a major cause of blindness, has greatly benefited from recent advances in retinal imaging.
- Conditions
- Retinitis Pigmentosa, Maculopathy, Age Related, Macular Dystrophy, Macular Edema
- Trial name
- AOSLO-OCT (NCT04620876)
- Testing
- Bimodal high resolution imaging of the retina
- Where
- France
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
AMD - Age-Related Macular Degeneration, Retinitis Pigmentosa (RP)
Retinal Investigation Using Optos OCT Device
Retinal investigation using OCT with control and diseased eyes
- Conditions
- AMD - Age-Related Macular Degeneration, Retinitis Pigmentosa (RP), Diabetic Retinopathy, Control Patients
- Trial name
- NCT06846151
- Testing
- retinal functional imaging
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Optos, PLC
Retinitis Pigmentosa
Transcorneal Electrostimulation for Therapy of Retinitis Pigmentosa
The purpose of this study is to determine the long-term effects of transcorneal electrostimulation (TcES) in patients with retinitis pigmentosa (RP).
- Trial name
- NCT01837901
- Testing
- Transcorneal electrostimulation
- Where
- Germany
- Volunteers
- 88 people
- Sponsor
- Okuvision GmbH
Retinitis Pigmentosa
Management of Retinitis Pigmentosa Via Electromagnetic Stimulation and Platelet Rich Plasma
The aim of this study is to investigate whether natural progression rate can be slowed down with subtenon PRP or PRP application combined with rEMS in retinitis pigmentosa cases.
- Trial name
- rEMS (NCT04252534)
- Testing
- PRP combined Magnovision, PRP
- Volunteers
- 60 people
- Sponsor
- Ankara Universitesi Teknokent
Retinitis Pigmentosa
Coloured-light in Retinitis Pigmentosa.
This study will assess the effect of 2 different colours of light on colour vision in adults with retinitis pigments (RP). Participants will be 18 years or above with a genetically confirmed molecular diagnosis of RP.
- Trial name
- CLIRP (NCT06224114)
- Testing
- Coloured-light torch, Different coloured-light torch
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- University College, London
Outer Retinal Degeneration, Retinitis Pigmentosa
Argus® II Retinal Prosthesis System Post-Market Surveillance Study
This post-market surveillance study is conducted in the European Economic Area where Argus II has been CE certified for use in outer retinal degeneration patients.
- Trial name
- NCT01490827
- Where
- 10 sites in Germany, Italy
- Volunteers
- 52 people
- Sponsor
- Second Sight Medical Products
Retinal Dystrophy, PRPF31 Mutationassociated Retinal Dystrophy
SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects
A Phase 1 Open-Label, Single Arm Dose Escalation Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy
- Conditions
- Retinal Dystrophy, PRPF31 Mutationassociated Retinal Dystrophy, RP11
- Trial name
- Platypus (NCT05902962)
- Testing
- VP-001
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- PYC Therapeutics
Usher Syndrome, Retinitis Pigmentosa
Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B
To evaluate the safety and tolerability of ascending doses of subretinal injections of SAR421869 in participants with Usher syndrome type 1B. To evaluate for possible biological activity of SAR421869.
- Trial name
- NCT01505062
- Testing
- SAR421869
- Where
- 2 sites in United States, France
- Volunteers
- 9 people
- Sponsor
- Sanofi
Retinitis Pigmentosa (RP)
Subthreshold Micropulse Laser Therapy (SML) in Retinitis Pigmentosa
Introduction Retinitis pigmentosa (RP) is the most common form of genetic retinal degenerative disease. The disease is progressive and leads to blindness and permanent disability within a few years of diagnosis.
- Trial name
- NCT07088705
- Testing
- SML 577 nm, SML 810 nm
- Where
- Poland
- Volunteers
- 60 people
- Sponsor
- Marta P. Wiącek
Retinitis Pigmentosa, Retinal Degeneration
Safety and Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients
Patients suffering from hereditary retinal degeneration receive a retinal implant to restore sight. Subretinal implant "ON" results in significant visual acuity improvement, when compared to "OFF" condition.
- Trial name
- NCT01024803
- Testing
- Device name: "Retina Implant model Alpha". Surgical implantation of medical device into eye
- Where
- 6 sites in Germany, Hungary and 1 more
- Volunteers
- 39 people
- Sponsor
- Retina Implant AG
Retinitis Pigmentosa
Acupuncture for the Treatment of Vision Loss Due to Retinitis Pigmentosa
Retinitis Pigmentosa (RP) patients are interested in trying alternative therapies to attempt to slow, halt or reverse the retinal disease process, and claim success with some approaches such as acupuncture, but this potential…
- Trial name
- NCT01604356
- Testing
- Electro-acupuncture
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Johns Hopkins University
Inherited Retinal Dystrophy, Inherited Retinal Disease
Safety and Efficacy Study of PUMCH-E111 Injection in Subjects With RLBP1 Related Inherited Retinal Dystrophy
The goal of this clinical trial is to evaluate the safety and efficacy of PUMCH-E111 injection in subjects with RLBP1 related Inherited Retinal Dystrophy.
- Trial name
- NCT07656753
- Testing
- PUMCH-E111 Injection（Low dose）, PUMCH-E111 Injection（High dose）
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Peking Union Medical College Hospital
Leber Hereditary Optic Neuropathy
Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year
The goal of this clinical trial is to assess the efficacy and safety of GS010 gene therapy - (lenadogene nolparvovec) in subjects with LHON due to the G11778A ND4 mitochondrial mutation with a vision loss up to one year.
- Trial name
- REFLECT (NCT03293524)
- Testing
- GS010
- Where
- 13 sites in United States, Belgium and 5 more
- Volunteers
- 98 people
- Sponsor
- GenSight Biologics